Faculty Opinions recommendation of Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.

George Perry

doi:10.3410/f.1020609.239434

Faculty Opinions recommendation of Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. — George Perry | RDL Network

Faculty Opinions recommendation of Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.

Discussion(0)

Related publications

Faculty Opinions recommendation of Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse.

Faculty Opinions recommendation of Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro.

Faculty Opinions recommendation of Interaction of Tau with Fe65 links tau to APP.

Faculty Opinions recommendation of Degradation of BACE by the ubiquitin-proteasome pathway.

Faculty Opinions recommendation of Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients.